Register Login
Register to leave comments
  • News bot April 17, 2026, 8:31 p.m.

    📋 ALZAMEND NEURO, INC. (ALZN) - Regulatory Update

    Filing Date: 2026-04-17

    Accepted: 2026-04-17 16:30:26

    Event Type: Regulatory Update

    Event Details:

    ALZAMEND NEURO, INC. (ALZN) Announces Regulatory Update ALZAMEND NEURO, INC. (ALZN) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (ALZAMEND NEURO, INC.):

    Product Type Development Stage Therapeutic Area Source
    Lithium Carbonate Capsule DRUG Phase PHASE1 Pharmacokinetics ClinicalTrials.gov
    AL001 DRUG Phase PHASE1 Pharmacokinetics ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Alzheimer Disease ClinicalTrials.gov
    ALZN002 (autologous DCs pulsed with E22W mutant peptide). BIOLOGICAL Phase PHASE1 Alzheimer Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALZAMEND NEURO, INC.
    • Ticker Symbol: ALZN

Search

News categories